2019 About APS EB 2019 Information

Hot Topics in Muscle Biology

Flex Session-NonFunded — Monday, April 8, 2019 — 8:30 AM - 10:00 AM — Convention Center, Room W312A
Muscle Biology Group — Chair: Xiaonan Wang — Co-Chair: William E. Mitch

The session highlights the impact that treatment of muscle atrophy exerts on metabolic disease outcomes. It will provide valuable current information for investigators that study muscle biology, physiology and pathology. These diseases include, but are not limited to, diabetes, cancer, chronic kidney disease, sepsis, chronic heart disease, and burn injury. It has been widely reported that treatment of muscle wasting has benefits in other organs. Skeletal muscle is a metabolically active tissue that communicates with other organs through active secretion (1). Loss of muscle mass during metabolic diseases can contribute to organ failure, and maintaining muscle mass can improve clinical outcomes (3, 11). Muscle derived cytokines, peptides, mRNA and microRNA have been shown to mediate crosstalk with other organs including bone, brain, cardiovascular system, liver, pancreas, skin, adipose tissue and kidney (2, 3, 6-8, 10). The clinical benefit of these muscle-derived factors makes them promising candidates for treating a myriad of metabolic diseases. The mechanism by which these muscle-derived factors exert their benefit remains largely unknown, and little is known about how these factors are transferred from skeletal muscle to organs. Recently, the number of studies on the impact of exosomes on muscle biology and physiology has dramatically increased. Growing evidence indicates that exosomes significantly influence muscle growth, regeneration and metabolism. However, our understanding of the effect of exosomes on control of muscle mass is in its infancy. Exosomes, one type of extracellular vesicle, are differentiated by size (30-100 nm). These vesicles contain a specific subset of proteins, mRNAs, microRNAs (miR), lipids and metabolites reflecting their originating cell types and conditions (9). Diverse therapeutic approaches have been pursued to utilize exosomes for delivery of vaccines, chemotherapeutic drugs and siRNA (4). Both pre-miRNAs and mature miRNA have been detected in exosomes, and miRs that are packaged in exosomes are quite stable (5). Importantly, exosomes provide a muscle to organ communication pathway under both normal physiological and pathophysiological conditions. This session will concentrate on the evidence of muscle-organ crosstalk mediated by various exosome cargos.This session will be useful and instructive for people studying muscle biology, physiology and pathology (Muscle Biology Group and nutrition physiology interest group); exosome and microRNA (e.g. the cell & molecular biology section of ASBMB); cardiac diseases (cardiovascular section of the APS); renal disease (renal section of APS); diabetes (Endocrinology & metabolism section); therapy strategy (ASPET) and systemic diseases that are characterized by muscle wasting (e.g. cancer sepsis, et al).


  • Muscle-Kidney Cross-Talk: miR23, Sarcopenia and Renal Fibrosis in Chronic Diseases
    Stephen Russ Price — Dept. of Biochemistry and Molec. Biology, Brody Sch. of Med. at East Carolina Univ.

  • Abstract
    Thomas Bodnar —

  • Abstract
    Bin Wang —

  • Abstract
    Joseph Gordon —

  • Abstract
    Aiqing Zhang —

Host Societies

Experimental Biology is the annual meeting of five Host Societies. By becoming a member of one of the societies below before registering, you can save up to $200 off the price of regular registration. Click a Host Society logo below to join today and save:

Copyright © Experimental Biology (EB) | Experimental Biology® is a federally registered trademark of EB.